Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Followed by an Open-Label Extension Phase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 24 Oct 2018 Results published in the Journal of Pain
- 24 Jun 2016 This trial was discontinued in France.
- 14 May 2016 Results presented at the 35th Annual Scientific Meeting of the American Pain Society